pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›PROSCAR
drug · small molecule
save

PROSCAR

Marketedupdated 3mo ago
/ fi-NA-stə-RYDE /
by $OGN Organon & Co.🔗 ChEMBL
Approved
community read0 votes

🐶 often sniffed alongside

top 4
  • tagApproval192 co-mentions · 55 sources
  • drugfinasteride97 co-mentions · 56 sources
  • tagSmall Molecule96 co-mentions · 55 sources
  • tagRecall1 co-mentions · 1 sources

Small molecule drug with a maximum clinical stage of Approval (across all indications), with 4 approved and 6 investigational indications.

targets

3-oxo-5-alpha-steroid 4-dehydrogenase 2

all catalysts(41)

approval · 41
Jun 19, 1992
approval
$OGN13.72+0.15%
34y ago
PROSCAR (FINASTERIDE) — FDA approval
PROSCAR
→
Aug 20, 1992
approval
$OGN13.72+0.15%
34y ago
PROSCAR (FINASTERIDE) — FDA approval
PROSCAR
→
Dec 22, 1992
approval
$OGN13.72+0.15%
34y ago
PROSCAR (FINASTERIDE) — FDA approval
PROSCAR
→
Dec 22, 1992
approval
$OGN13.72+0.15%
34y ago
PROSCAR (FINASTERIDE) — FDA approval
PROSCAR
→
Apr 5, 1993
approval
$OGN13.72+0.15%
33y ago
PROSCAR (FINASTERIDE) — FDA approval
PROSCAR
→
Sep 1, 1993
approval
$OGN13.72+0.15%
33y ago
PROSCAR (FINASTERIDE) — FDA approval
PROSCAR
→
Sep 16, 1993
approval
$OGN13.72+0.15%
33y ago
PROSCAR (FINASTERIDE) — FDA approval
PROSCAR
→
May 18, 1994
approval
$OGN13.72+0.15%
32y ago
PROSCAR (FINASTERIDE) — FDA approval
PROSCAR
→
May 18, 1994
approval
$OGN13.72+0.15%
32y ago
PROSCAR (FINASTERIDE) — FDA approval
PROSCAR
→
Dec 30, 1994
approval
$OGN13.72+0.15%
32y ago
PROSCAR (FINASTERIDE) — FDA approval
PROSCAR
→
Jul 24, 1996
approval
$OGN13.72+0.15%
30y ago
PROSCAR (FINASTERIDE) — FDA approval
PROSCAR
→
Aug 28, 1996
approval
$OGN13.72+0.15%
30y ago
PROSCAR (FINASTERIDE) — FDA approval
PROSCAR
→
May 12, 1997
approval
$OGN13.72+0.15%
29y ago
PROSCAR (FINASTERIDE) — FDA approval
PROSCAR
→
May 16, 1997
approval
$OGN13.72+0.15%
29y ago
PROSCAR (FINASTERIDE) — FDA approval
PROSCAR
→
Dec 19, 1997
approval
$OGN13.72+0.15%
29y ago
PROSCAR (FINASTERIDE) — FDA approval
PROSCAR
→
Mar 20, 1998
approval
$OGN13.72+0.15%
28y ago
PROSCAR (FINASTERIDE) — FDA approval
PROSCAR
→
Mar 20, 1998
approval
$OGN13.72+0.15%
28y ago
PROSCAR (FINASTERIDE) — FDA approval
PROSCAR
→
Aug 2, 1999
approval
$OGN13.72+0.15%
27y ago
PROSCAR (FINASTERIDE) — FDA approval
PROSCAR
→
Jan 17, 2001
approval
$OGN13.72+0.15%
26y ago
PROSCAR (FINASTERIDE) — FDA approval
PROSCAR
→
Jan 30, 2001
approval
$OGN13.72+0.15%
26y ago
PROSCAR (FINASTERIDE) — FDA approval
PROSCAR
→
Oct 28, 2002
approval
$OGN13.72+0.15%
24y ago
PROSCAR (FINASTERIDE) — FDA approval
PROSCAR
→
Nov 26, 2002
approval
$OGN13.72+0.15%
24y ago
PROSCAR (FINASTERIDE) — FDA approval
PROSCAR
→
Jun 26, 2003
approval
$OGN13.72+0.15%
23y ago
PROSCAR (FINASTERIDE) — FDA approval
PROSCAR
→
Sep 9, 2003
approval
$OGN13.72+0.15%
23y ago
PROSCAR (FINASTERIDE) — FDA approval
PROSCAR
→
Sep 23, 2003
approval
$OGN13.72+0.15%
23y ago
PROSCAR (FINASTERIDE) — FDA approval
PROSCAR
→
Apr 12, 2004
approval
$OGN13.72+0.15%
22y ago
PROSCAR (FINASTERIDE) — FDA approval
PROSCAR
→
Apr 23, 2004
approval
$OGN13.72+0.15%
22y ago
PROSCAR (FINASTERIDE) — FDA approval
PROSCAR
→
Mar 23, 2010
approval
$OGN13.72+0.15%
16y ago
PROSCAR (FINASTERIDE) — FDA approval
PROSCAR
→
Oct 4, 2010
approval
$OGN13.72+0.15%
16y ago
PROSCAR (FINASTERIDE) — FDA approval
PROSCAR
→
Jun 9, 2011
approval
$OGN13.72+0.15%
15y ago
PROSCAR (FINASTERIDE) — FDA approval
PROSCAR
→
Jun 10, 2011
approval
$OGN13.72+0.15%
15y ago
PROSCAR (FINASTERIDE) — FDA approval
PROSCAR
→
Apr 11, 2012
approval
$OGN13.72+0.15%
14y ago
PROSCAR (FINASTERIDE) — FDA approval
PROSCAR
→
Apr 11, 2012
approval
$OGN13.72+0.15%
14y ago
PROSCAR (FINASTERIDE) — FDA approval
PROSCAR
→
Apr 11, 2012
approval
$OGN13.72+0.15%
14y ago
PROSCAR (FINASTERIDE) — FDA approval
PROSCAR
→
Jan 16, 2013
approval
$OGN13.72+0.15%
14y ago
PROSCAR (FINASTERIDE) — FDA approval
PROSCAR
→
Mar 11, 2014
approval
$OGN13.72+0.15%
12y ago
PROSCAR (FINASTERIDE) — FDA approval
PROSCAR
→
Jul 6, 2015
approval
$OGN13.72+0.15%
11y ago
PROSCAR (FINASTERIDE) — FDA approval
PROSCAR
→
Apr 13, 2021
approval
$OGN13.72+0.15%
5y ago
PROSCAR (FINASTERIDE) — FDA approval
PROSCAR
→
Jun 15, 2021
approval
$OGN13.72+0.15%
5y ago
PROSCAR (FINASTERIDE) — FDA approval
PROSCAR
→
Aug 25, 2021
approval
$OGN13.72+0.15%
5y ago
PROSCAR (FINASTERIDE) — FDA approval
PROSCAR
→
Mar 18, 2026
approval
$OGN13.72+0.15%
5mo ago
PROSCAR (FINASTERIDE) — FDA approval
PROSCAR
→
view all 41 catalysts →

Trials studying PROSCAR

  • phase2Clinical Trial to Evaluate CG2001 in Chinese Adult Male Participants With Androgenetic Alopeciacompletedn=110
  • phase1Study to Evaluate the Drug-drug Interaction Between IY001 and IY002 in Healthy Adult Male Subjects.completedn=43
  • phase3Efficacy and Safety of Finlândia Hair Lotion Association on Androgenetic Alopeciarecruitingn=190
  • N/ABenefits of a Cosmetic Anti-hair Loss in Males With Hair Lossnot yet recruitingn=140
  • phase1Finasteride 5 mg Tablets Under Fasting Conditionscompletedn=32
  • phase1Finasteride 5 mg Tablets, Non-fastingcompletedn=20
  • phase3A Study of an Investigational Study Drug for Benign Prostatic Hyperplasia (0906-140)completedn=600
  • phase1Fasting Study of Finasteride Tablets 5 mg and Proscar Tablets 5 mgcompletedn=29
more trials →

News(2)

  • Veradermics keeps ‘momentum going’ as baldness drug helps women with hair loss
    The Phase 2 data exceeded expectations, lifting company shares as high as nearly $130 apiece and building the case for what may be the first pill specifically approved for female pattern hair loss.
    biopharma_dive · 29d ago
  • Veradermics soars on positive data for baldness treatment
    The results could support the first approval in decades for an oral medicine that can treat male pattern baldness, though the therapy will face competition from generics and over-the-counter medica…
    biopharma_dive · 3mo ago
brand
PROSCAR
trade names
Aindeem, Finasteride, Finasteride component of entadfi, Propecia, Proscar, Prostide
generic
FINASTERIDE
MOA
12.1 Mechanism of Action The development and enlargement of the prostate gland is dependent on the potent androgen, 5α-dihydrotestosterone (DHT). Type II 5α-reductase metabolizes testosterone to DHT in the prostate gland, liver and skin. DHT induces androgenic effects by binding to androgen receptors in the cell nuclei of these organs. Finasteride is a competitive and specific inhibitor of Type II 5α-reductase with which it slowly forms a stable enzyme complex. Turnover from this complex is extremely slow (t ½ ~ 30 days). This has been demonstrated both in vivo and in vitro . Finasteride has no affinity for the androgen receptor. In man, the 5α-reduced steroid metabolites in blood and urine are decreased after administration of finasteride.
phase
marketed
Data sources
openFDA · ClinicalTrials.gov · OpenTargets
last refreshed 26m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?